Nuwellis, Inc. (NASDAQ:NUWE) Q3 2023 Earnings Call Transcript

Anthony Vendetti: Great. Okay, thank you very much. Appreciate it. I’ll hop back in queue.

Nestor Jaramillo: Thank you.

Operator: Seeing that there are no further questions. I would like to turn the conference back over to Nestor Jaramillo for closing remarks.

Nestor Jaramillo: Thank you, operator. We are deeply encouraged by our progress across multiple initiatives, including organic growth in our core business. We believe the success of our DaVita pilot program will lead to ultrafiltration service approval, expanding ultrafiltration therapy, and meaningfully accelerate our revenue growth and path to profitability. To this, we add new product opportunities in our high growth pediatric category with the SeaStar SCD device targeted for marketing approval for commercialization by year end 2023 or early 2024, depending on the approval. Finally, we with increased awareness of our body of clinical and economic evidence. We are continued to advance market penetration in our ultrafiltration therapy with healthy growth in therapy utilization, in our heart failure, critical care, and pediatric categories.

As we conclude our call, I would like to thank all our stakeholders as well as employees, stockholders, physician, nurses, patients, and health care workers in the field. We have a full and exciting lineup of opportunities ahead and appreciate your continued support as we drive meaningful progress in our initiatives to transform the lives of patients suffering from fluid overload with our Aquadex system ultrafiltration therapy. Thank you.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.